Opportunities in pharmacogenomics for the treatment of Alzheimer’s disease

Abstract excerpt

In Alzheimer's disease (AD), approximately 10–20% of direct costs are associated with pharmacological treatment. Pharmacogenomics account for 30–90% variability in pharmacokinetics and pharmacodynamics. Genes potentially involved in the pharmacogenomics outcome include pathogenic, mechanistic, metabolic, transporter and pleiotropic genes. Over 75% of the Caucasian population is defective for the CYP2D6+2C9+2C19 cl...

Topics

Open a Topic to create a Post that cites this publication.

• Cholinesterase and Neurodegenerative Diseases
• Computational Drug Discovery Methods
• Pharmacogenetics and Drug Metabolism

Identifiers and source

Literature Corpus work

372cdbd7-caad-5629-a1e6-dc38eafff3a0

DOI

10.2217/fnl.15.12